Figure 2.
The anti-PTHrP M158 mAb enhances doxorubicin cytoreductive action on TNBC cell lines. Growth curves illustrating combinatorial treatment using increasing doses of mAb M158 and doxorubicin. MDA-MB-231, BT-549 and MDA-MB-435 are PTHrP-positive while MDA-MB-468 is PTHrP-negative. Curves are representative of a set of 3 replicates.